要点诺和诺德(Novo Nordisk)赢得了一场重大的法律胜利,这在很大程度上限制了调配药房推销或销售该制药公司的畅销减肥药维格威(Wegovy)和糖尿病治疗药物奥泽美(Ozempic)的更便宜、未经批准的版本。美国地方法院法官马克・皮特曼(Mark Pittman)驳回了外包设施协会(Outsourcing Facilities Association)提出的初步禁令申请,该禁令本欲阻止美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.